<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80487">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01747447</url>
  </required_header>
  <id_info>
    <org_study_id>2012P000560</org_study_id>
    <secondary_id>5R01AR060574-03</secondary_id>
    <nct_id>NCT01747447</nct_id>
  </id_info>
  <brief_title>VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture</brief_title>
  <acronym>VITAL</acronym>
  <official_title>VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in
      20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin
      D3 (2000 IU) or fish oil (1 gram of omega-3 fatty acids) reduces the risk of developing
      cancer, heart disease, and stroke in people who do not have a prior history of these
      illnesses. This ancillary study is being conducted among a sub-cohort of 600 participants in
      VITAL and will test the efficacy and safety of high-dose vitamin D supplementation vs.
      placebo on skeletal health and body composition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The VITAL: Effects on Bone Structure and Architecture is an ancillary study of the parent
      VITAL. This study will enroll a sub-cohort of 600 VITAL participants at the NIH-sponsored
      Harvard Catalyst Clinical and Translational Science Center (CTSC). The following
      measurements will be performed at baseline and 2 years post-randomization to determine
      whether high-dose vitamin D supplementation vs. placebo: 1) Produces small increases or
      reduces bone loss in spine, hip, and total body areal bone density as assessed by DXA; 2)
      reduces bone turnover as assessed by biomarkers of bone resorption and formation; 3)
      Improves measures of bone structure at the distal radius and tibia; 4) results in changes in
      body composition assessed by DXA. Parallel assessments of the effects of omega-3 fatty acids
      will be performed. This study may elucidate the mechanisms through which high-dose vitamin D
      may prevent age-related fractures and provide new insights into the role of vitamin D on
      skeletal health and body composition.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Bone density</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine whether vitamin D and/or fish oil supplementation produces small increases or reduces bone loss in spine, hip, and total body areal bone density,as assessed by DXA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Turnover</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine whether vitamin D and/or fish oil supplementation reduces bone turnover, as assessed biomarkers of bone resorption and bone formation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Structure</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine whether vitamin D and/or fish oil supplementation results in changes in bone structure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body Composition</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine whether vitamin D and/or fish oil supplementation results in changes in body composition as assessed by DXA: total body fat and lean mass, and fat mass index and lean mass index, regional fat and lean mass and derived ratios.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Bone Density</condition>
  <condition>Body Composition</condition>
  <condition>Bone Health</condition>
  <arm_group>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D  + fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 placebo</intervention_name>
    <description>Vitamin D placebo</description>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fish oil placebo</intervention_name>
    <description>Fish oil placebo</description>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 fatty acids (fish oil)</intervention_name>
    <description>Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
    <arm_group_label>Vitamin D  + fish oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 (cholecalciferol), 2000 IU per day.</description>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
    <arm_group_label>Vitamin D  + fish oil</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participants in VITAL (NCT 01169259) who meet the following criteria are eligible to
        participate in this ancillary study:

          -  Those who are using bisphosphonates currently or within the past 2 years, or other
             bone-active medications currently or within the past year are not eligible for this
             study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meryl S LeBoff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>December 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Meryl LeBoff</investigator_full_name>
    <investigator_title>Director of Skeletal Health and Osteoporosis Center</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
